Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors

被引：28
|
作者：
Zhang, Long [1 ]
Yang, Yingying [1 ]
Zhou, Haojie [1 ]
Zheng, Qingmei [1 ]
Li, Yuhao [1 ]
Zheng, Shansong [1 ]
Zhao, Shuyong [1 ]
Chen, Dong [1 ]
Fan, Chuanwen [1 ]
机构：
[1] Qilu Pharmaceut Co Ltd, Shandong Prov Key Lab Small Mol Targeted Drugs, Jinan 250100, Shandong, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2015年 / 102卷
关键词：
Quinazoline derivatives; H1975; EGFR-T790M; HCC827; A-431; GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; IRREVERSIBLE INHIBITORS; EGFR INHIBITOR; ACQUIRED-RESISTANCE; T790M MUTATION; PHASE-II; GEFITINIB; 4-(PHENYLAMINO)QUINAZOLINE;
D O I：
10.1016/j.ejmech.2015.08.026
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
We have developed a series of 6, 7-disubstituted-4-(arylamino) quinazoline derivatives that functioned as irreversible EGFR inhibitors, and these compounds exhibited excellent enzyme inhibition potency. As compared with afatinib, some of them showed significantly enhanced activities towards H1975 cells (EGFR-T790M). Furthermore, the optimized compounds 7q and 8f also demonstrated good pharmacokinetic profiles, oral bioavailability as well as excellent in vivo efficacy in H1975 and HCC827 xenografts at a non-toxic dose. Based on the improved safety and efficacy against EGFR-T790M resistance, 7q and 8f are promising candidates for further studies. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：445 / 463
页数：19
相关论文
共 50 条
  • [1] Discovery of selective irreversible inhibitors for EGFR-T790M
    Zhou, Wenjun
    Ercan, Dalia
    Jaenne, Pasi A.
    Gray, Nathanael S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (02) : 638 - 643
  • [2] Discovery of novel selective inhibitors for EGFR-T790M/L858R
    Bai, Fang
    Liu, Hongyan
    Tong, Linjiang
    Zhou, Wei
    Liu, Li
    Zhao, Zhenjiang
    Liu, Xiaofeng
    Jiang, Hualiang
    Wang, Xicheng
    Xie, Hua
    Li, Honglin
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (03) : 1365 - 1370
  • [3] In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors
    Asadollahi-Baboli, M.
    MOLECULAR DIVERSITY, 2016, 20 (03) : 729 - 739
  • [4] In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors
    M. Asadollahi-Baboli
    Molecular Diversity, 2016, 20 : 729 - 739
  • [5] Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors
    Tu, Yuanbiao
    Wang, Caolin
    Yang, Zunhua
    Zhao, Bingbing
    Lai, Luogen
    Yang, Qi
    Zheng, Pengwu
    Zhu, Wufu
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2018, 16 : 462 - 478
  • [6] Discovery of a potent dual ALK and EGFR T790M inhibitor
    Jang, Jaebong
    Son, Jung Beom
    To, Ciric
    Bahcall, Magda
    Kim, So Young
    Kang, Seock Yong
    Mushajiang, Mierzhati
    Lee, Younho
    Janne, Pasi A.
    Choi, Hwan Geun
    Gray, Nathanael S.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 136 : 497 - 510
  • [7] EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity
    Vikis, Haris
    Sato, Mitsuo
    James, Michael
    Wang, Daolong
    Wang, Yian
    Wang, Min
    Jia, Dongmei
    Liu, Yan
    Bailey-Wilson, Joan E.
    Amos, Christopher I.
    Pinney, Susan M.
    Petersen, Gloria M.
    de Andrade, Mariza
    Yang, Ping
    Wiest, Jonathan S.
    Fain, Pamela R.
    Schwartz, Ann G.
    Gazdar, Adi
    Gaba, Colette
    Rothschild, Henry
    Mandal, Diptasri
    Kupert, Elena
    Seminara, Daniela
    Viswanathan, Avinash
    Govindan, Ramaswamy
    Minna, John
    Anderson, Marshall W.
    You, Ming
    CANCER RESEARCH, 2007, 67 (10) : 4665 - 4670
  • [8] Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M
    Costa, Daniel B.
    Kobayashi, Susumu S.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (06) : 809 - 815
  • [9] In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features
    Xiang, Mingli
    Lei, Kai
    Fan, Wenjie
    Lin, Yuchun
    He, Gu
    Yang, Mingli
    Chen, Lijuan
    Mo, Yirong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 : 789 - 839
  • [10] Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present)
    Sandor, Alexandru
    Ionut, Ioana
    Marc, Gabriel
    Oniga, Ilioara
    Eniu, Dan
    Oniga, Ovidiu
    PHARMACEUTICALS, 2023, 16 (04)
12345